Lesley Fallowfield|Judith Bliss|Lucy Porter|Miranda H. Price|Claire Snowdon|Stephen E. Jones|R. Charles Coombes|Emma Hall
Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer
Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Cancer Research UK|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex|Brighton and Sussex Medical School|Institute of Cancer Research|Cancer Research UK|Imperial College London|Texas Oncology|Institute of Cancer Research|University of Sussex
purpose compare describe quality life qol women allocated tamoxifen exemestane within intergroup exemestane study ies patients methods postmenopausal women primary breast cancer disease free 2 3 years randomly assigned switch tamoxifen exemestane continue tamoxifen 5 years treatment completed subset ies centers participated qol substudy functional assessment cancer therapybreast factb endocrine subscale es administered random assignment predefined followup times primary end point factb composite trial outcome index toi secondary end points included total factbes score total es score severity individual endocrine symptoms analysis reports qol 24 months results five hundred eightytwo patients eight countries enrolled onto substudy completion return questionnaires excellent 85 available analysis qol generally good stable 2 years clinically meaningful differences found groups toi es prevalence severe endocrine symptoms trial entry high vasomotor complaints sexual problems persisted groups study significant differences groups seen endocrine symptoms apart vaginal discharge pronounced tamoxifen p lt 001 conclusion switch tamoxifen exemestane neither increased decreased endocrine symptoms present 2 3 years tamoxifen switch also initiate significant reports new symptoms results indicate clinical benefits exemestane tamoxifen achieved without significant detrimental effect qol